Expand MIRM Menu
MIRM MENU

MIRM Latest Press Releases

-- August 11, 2026 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- August 5, 2026 --

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Business Wire 4:01 PM

-- July 29, 2026 --

Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 Business Wire 4:01 PM

-- July 13, 2026 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- June 14, 2026 --

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva Business Wire 4:35 PM

-- June 11, 2026 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- June 4, 2026 --

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 Business Wire 8:05 AM

-- May 30, 2026 --

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 Business Wire 12:00 PM

-- May 21, 2026 --

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026 Business Wire 8:05 AM

-- May 14, 2026 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- May 12, 2026 --

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes Business Wire 11:56 PM
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering Business Wire 4:01 PM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire 8:00 AM

-- May 6, 2026 --

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update Business Wire 4:01 PM

-- May 4, 2026 --

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis Business Wire 8:00 AM

-- May 3, 2026 --

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 Business Wire 5:00 PM

-- April 29, 2026 --

Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 Business Wire 4:01 PM

-- April 27, 2026 --

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus Business Wire 8:31 AM
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus Business Wire 8:00 AM

-- April 13, 2026 --

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- March 16, 2026 --

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Additional Rare Cholestatic Liver Diseases Business Wire 8:00 AM
Market Data Delayed 15 Minutes